British Association for Psychopharmacology (BAP) is a UK-based scientific society that promotes research and education in psychopharmacology—the study of how drugs affect mood, behaviour and mental processes. BAP supports both clinical and preclinical research and provides guidance on the use of medications in psychiatry through its evidence-based guidelines, conferences, and training events.
The annual BAP Summer Meeting took place this week in Manchester. The event showcases cutting-edge research, fosters collaboration among scientists and clinicians, supports early-career professionals, and promotes evidence-based practice in mental health. It features lectures, symposia, and awards like the Clinical Junior Award, all aimed at advancing the field of psychopharmacology.
We are delighted to extend our congratulations to Oxford Health Biomedical Research Centre (OH BRC) researcher and University of Oxford’s Department of Psychiatry Associate Professor Max Taquet who received the 2025 BAP Clinical Junior Award at this years event in relation to his research using electronic health records data to advance psychopharmacology research.
He told us, “I am truly honoured to have received this award, especially given the inspiring individuals who have received it before me. I am very grateful to the Department of Psychiatry and to OH BRC for fostering such a supportive and collaborative environment. It is a privilege to be able to pursue research in psychopharmacology here.”
The Clinical Junior Award is typically given to early-career clinicians or researchers who have made notable contributions to the field of psychopharmacology.
Contact us: ohbrcenquiries@oxfordhealth.nhs.uk
